Coloplast (CPSE:COLO B) - Aktienkurs, Nachrichten und Analyse

COLO B Aktienübersicht

Coloplast A/S entwickelt und vertreibt Produkte und Dienstleistungen im Bereich der Intimpflege in Dänemark, den Vereinigten Staaten, dem Vereinigten Königreich, Frankreich und international. Mehr Details

COLO B grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	3/6
Künftiges Wachstum	3/6
Vergangene Leistung	3/6
Finanzielle Gesundheit	2/6
Dividenden	3/6

Belohnungen

41% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 12.85% pro Jahr

Die Erträge sind in den letzten 5 Jahren um 4.9% pro Jahr gestiegen.

Risikoanalyse

Die Verschuldung ist durch den operativer Cashflow nicht gut gedeckt

Die Dividende von 2.47% ist nicht gut durch Erträge oder freie Cashflows gedeckt

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WarrenAI

Based on Analyst Price Targets

Operational Efficiencies And Innovations In Urology And Wound Care Propel Future Growth

Key Takeaways Improved operational efficiency and strategic expansions are expected to enhance net margins and earnings over the long term. Strategic acquisitions and growth in niche markets are projected to boost revenue and transform key business segments.

View narrative

DKK 911.19

2.3% undervalued

8.48%

Revenue growth p.a.

11 days ago

Coloplast A/S Wettbewerber

Demant

CPSE:DEMANT

DKK 57.7b

Ambu

CPSE:AMBU B

DKK 30.5b

Embla Medical hf

CPSE:EMBLA

DKK 15.3b

Cooper Companies

NasdaqGS:COO

US$19.8b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Coloplast
Historische Aktienkurse
Aktueller Aktienkurs	DKK 890.00
52-Wochen-Hoch	DKK 977.60
52-Wochen-Tief	DKK 739.60
Beta	0.34
11 Monat Veränderung	-0.71%
3 Monate Veränderung	0.25%
1 Jahr Veränderung	18.32%
33 Jahre Veränderung	-24.67%
5 Jahre Veränderung	11.33%
Veränderung seit IPO	6,865.22%

Aktuelle Nachrichten und Updates

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Nov 13

Earnings Update: Coloplast A/S (CPH:COLO B) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Nov 08

Recent updates

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Nov 13

Earnings Update: Coloplast A/S (CPH:COLO B) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Nov 08

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Oct 18

Coloplast A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Aug 23

Are Investors Undervaluing Coloplast A/S (CPH:COLO B) By 38%?

Aug 22

Subdued Growth No Barrier To Coloplast A/S' (CPH:COLO B) Price

Jul 17

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Jun 29

Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations

May 21

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of DKK5.00

May 10

Analyst Estimates: Here's What Brokers Think Of Coloplast A/S (CPH:COLO B) After Its Interim Report

May 09

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Dec 04

Coloplast (CPH:COLO B) Strong Profits May Be Masking Some Underlying Issues

Nov 16

A Look At The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Sep 30

Is Coloplast (CPH:COLO B) A Risky Investment?

Jun 28

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 18% Below Its Share Price

Jun 10

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Mar 22

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 25% Below Its Share Price

Mar 01

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Dec 14

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Nov 26

Here's Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Looks Fair for the time being

Nov 25

Coloplast's (CPH:COLO B) Shareholders Will Receive A Bigger Dividend Than Last Year

Nov 11

With EPS Growth And More, Coloplast (CPH:COLO B) Makes An Interesting Case

Oct 25

Estimating The Fair Value Of Coloplast A/S (CPH:COLO B)

Aug 26

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Jul 27

Here's Why We Think Coloplast (CPH:COLO B) Is Well Worth Watching

Jul 12

Is There An Opportunity With Coloplast A/S' (CPH:COLO B) 45% Undervaluation?

May 23

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of kr.5.00

May 08

Aktionärsrenditen

	COLO B	DK Medical Equipment	DK Markt
7D	-4.2%	-1.2%	-3.1%
1Y	18.3%	16.5%	5.7%

Rendite im Vergleich zur Industrie: COLO B übertraf die Branche Danish Medical Equipment , die im vergangenen Jahr eine Rendite von 16.5 erzielte.

Rendite vs. Markt: COLO B übertraf den Markt Danish, der im vergangenen Jahr eine Rendite von 5.7 erzielte.

Preisvolatilität

Is COLO B's price volatile compared to industry and market?
COLO B volatility
COLO B Average Weekly Movement	3.6%
Medical Equipment Industry Average Movement	3.7%
Market Average Movement	4.2%
10% most volatile stocks in DK Market	10.5%
10% least volatile stocks in DK Market	2.4%

Stabiler Aktienkurs: COLO B hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: COLO BDie wöchentliche Volatilität (4%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1954	16,639	Kristian Villumsen	www.coloplast.com

Coloplast A/S entwickelt und vertreibt Produkte und Dienstleistungen im Bereich der Intimpflege in Dänemark, den Vereinigten Staaten, Großbritannien, Frankreich und international. Das Unternehmen ist in den Segmenten Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology und Advanced Wound Care tätig. Es bietet Produkte für die Stomaversorgung an, darunter SenSura Mio, das sich an individuelle Körperformen anpasst und optimale Diskretion für verschiedene Arten von Stomata bietet, sowie SenSura Ostomy-Versorgungslösungen und Stomazubehör unter der Marke Brava.

Coloplast A/S's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Coloplast im Vergleich zum Marktanteil des Unternehmens?
COLO B grundlegende Statistiken
Marktanteil	DKK 200.37b
Gewinn(TTM)	DKK 5.05b
Umsatz(TTM)	DKK 27.03b

39.7x

Kurs-Gewinn-Verhältnis

7.4x

Kurs-Umsatz-Verhältnis

Ist COLO B zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
COLO B Gewinn- und Verlustrechnung (TTM)
Einnahmen	DKK 27.03b
Kosten der Einnahmen	DKK 8.76b
Bruttogewinn	DKK 18.27b
Sonstige Ausgaben	DKK 13.22b
Umsatz	DKK 5.05b

Zuletzt gemeldete Gewinne

Sep 30, 2024

Datum des nächsten Gewinnberichts

Feb 04, 2025

Gewinn per Aktie (EPS)	22.44
Bruttomarge	67.59%
Nettogewinnspanne	18.69%
Schulden/Eigenkapital-Verhältnis	120.6%

Wie hat sich COLO B auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

2.5%

Aktuelle Dividendenrendite

98%

Ausschüttungsquote

Zahlt COLO B eine zuverlässige Dividende?

Siehe COLO B Dividendenhistorie und Benchmarks

Bis wann müssen Sie COLO B kaufen, um eine kommende Dividende zu erhalten?
Coloplast Dividendentermine
Ex-Dividenden Datum	Dec 06 2024
Datum der Dividendenzahlung	Dec 10 2024
Tage bis Ex-Dividende	17 days
Tage bis zum Datum der Dividendenzahlung	21 days

Zahlt COLO B eine zuverlässige Dividende?

Siehe COLO B Dividendenhistorie und Benchmarks

COLO B Aktienübersicht

Belohnungen

Risikoanalyse

Operational Efficiencies And Innovations In Urology And Wound Care Propel Future Growth

Coloplast A/S Wettbewerber

CPSE:DEMANT

DKK 57.7b

CPSE:AMBU B

DKK 30.5b

CPSE:EMBLA

DKK 15.3b

NasdaqGS:COO

US$19.8b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Earnings Update: Coloplast A/S (CPH:COLO B) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Final dividend increased to kr.17.00

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Recent updates

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Earnings Update: Coloplast A/S (CPH:COLO B) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Final dividend increased to kr.17.00

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

President & CEO exercised options and sold kr.5.0m worth of stock

Executive Vice President of Growth exercised options to buy kr.28m worth of stock.

Coloplast A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Are Investors Undervaluing Coloplast A/S (CPH:COLO B) By 38%?

Third quarter 2024 earnings: EPS misses analyst expectations

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Subdued Growth No Barrier To Coloplast A/S' (CPH:COLO B) Price

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of DKK5.00

First half dividend of kr.5.00 announced

Analyst Estimates: Here's What Brokers Think Of Coloplast A/S (CPH:COLO B) After Its Interim Report

Coloplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24

Second quarter 2024 earnings: EPS misses analyst expectations

A Look At The Fair Value Of Coloplast A/S (CPH:COLO B)

There's Reason For Concern Over Coloplast A/S' (CPH:COLO B) Price

Is Coloplast (CPH:COLO B) A Risky Investment?

President & CEO exercised options and sold kr.13m worth of stock

First quarter 2024 earnings: Revenues in line with analyst expectations

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Estimating The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Coloplast A/S' (CPH:COLO B) Price Is Out Of Tune With Earnings

Coloplast A/S Approves the Distribution of Year-End Dividend

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast (CPH:COLO B) Strong Profits May Be Masking Some Underlying Issues

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Now 20% undervalued after recent price drop

A Look At The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Deputy Chairman recently bought kr.40m worth of stock

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

New minor risk - Shareholder dilution

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Is Coloplast (CPH:COLO B) A Risky Investment?

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 18% Below Its Share Price

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 25% Below Its Share Price

First quarter 2023 earnings: EPS misses analyst expectations

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Upcoming dividend of kr.15.00 per share

Here's Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Looks Fair for the time being

Erträge & Einnahmen